AKNEMYCIN PLUS, ERYTHROMYCIN PH EUR

Posology To be applied to the affected areas once or twice daily. Treatment should continue for 9-12 weeks according to the condition of the skin. It should be noted that therapeutic improvement may not be observed for several weeks after starting treatment.

Consistent application makes a significant contribution to the success of the therapy. Excess application of Aknemycin Plus should be avoided since it may result in marked erythema, drying and discomfort of the treated areas. The dosage is the same for all ages.

Method of administration For application to the skin. The applicator allows direct administration to the skin. The patient should press the top of the screw cap on the foam pad before each use and should feel a 'click' which indicates that the applicator will close again automatically.

The following frequency categories are used for the evaluation of undesirable effects: Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (frequency cannot be estimated from the available data) Skin and subcutaneous tissue disorders: There may be rare cases of skin irritation in the form of erythema, burning, drying or peeling of the skin may be observed.

There may be an apparent deterioration in acne with an increase in inflammatory symptoms at the commencement of treatment; this is a sign that the medicine is beginning to act and is usually transitory. If the above occurs, treatment should not be interrupted but the frequency of application reduced.

Rarely, a temporary hypopigmentation or hyperpigmentation has been reported in individuals treated with tretinoin. Temporary depigmentation in non-caucasians is possible. Not known: acute generalised exanthematous pustulosis (AGEP). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Photosensitivity may occur during treatment with Aknemycin Plus. Exposure to sunlight should be minimised and use of sun lamps or sun beds avoided during treatment. Patients with sunburn should not use this product until recovered because of the increased susceptibility to sunlight whilst using tretinoin.

Wind and rain may be unusually irritating to patients under treatment. Accumulation of the product in skin folds or in the angles of the nose should be avoided. The product should not be allowed to come into contact with the eyes or eyelids - if this occurs, thorough rinsing with water is recommended.

As with other macrolides, rare serious allergic reactions, including acute generalised exanthematous pustulosis (AGEP) have been reported. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted.

Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued. This medicine contains 752 mg of alcohol (ethanol) in each ml. It may cause burning sensation on damaged skin. Do not light a cigarette or expose yourself to flame until the medicine has dried completely.

1. • A family history of cutaneous epithelioma. • In acute eczemas, rosacea and acute inflammatory conditions of the skin, especially around the mouth. 5). 6) • Women planning a pregnancy.